PubRank

Odile Beyne-Rauzy

Author PubWeight™ 39.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011 3.28
2 Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013 3.10
3 Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2010 3.06
4 Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2008 2.39
5 TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009 2.18
6 Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol 2013 2.03
7 Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2004 2.03
8 TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009 1.95
9 Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010 1.93
10 Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012 1.88
11 Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2007 1.67
12 Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011 1.61
13 Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. Leuk Res 2011 1.55
14 The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008 1.48
15 Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 2010 1.47
16 Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 2004 1.38
17 Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010 1.02
18 A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies. Br J Haematol 2005 0.85
19 Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2014 0.84
20 Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 2013 0.83
21 Anti-PCNA antibodies: prevalence and predictive value. Joint Bone Spine 2005 0.81
22 Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica 2009 0.81
23 Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. Emerg Infect Dis 2015 0.77
24 Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. Am J Hematol 2014 0.77
25 Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 2014 0.77
26 [The prognosis of gestational pemphigoides]. Presse Med 2004 0.75